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Background: High serum brain natriuretic peptide (BNP) (>400 pg/ml) is associated
with high morbidity and mortality following Transcatheter Aortic Valve Replacement
(TAVR). However, whether TA is associated with a distinct humoral response pattern
has not been established.
Methods: We compared the BNP distribution (median and IQR) at baseline and at
hospital discharge following TAVR stratiﬁed according into those who underwent
transapical (TA) or transfemoral (TF) approach.
Results: A total of 217 patients underwent TAVR for symptomatic aortic stenosis. The
mean age was 84  7 years-old and 27% (n¼60) underwent TA approach. The preva-
lence of left ventricular ejection fraction (LVEF) 40% (27% vs. 20%; p¼0.3), chronic
renal failure (62% vs. 59; p¼0.7) and the baselinemedian BNP levels were comparable in
the TA and TF groups (TA median¼368, [IQR 25th-75th ¼ 205-591]); TF
median¼338 [176-584]; p¼0.6). At discharge, the BNP levels paradoxically increased in
the TA (TAmedian¼ 698 [465-989]) approach as opposed to the TF (TFmedian¼319
[176-584]); p<0.001 (ﬁgure). The echocardiograph correlates for BNP at discharge
were: LVEF (r ¼ -0.49; p<0.01), left ventricular outﬂow tract diameter (r ¼ -0.48;
p<0.03) and the residual aortic mean aortic gradient (r ¼ -0.18; p<0.02).
Conclusion: Patients undergoing TAVR by TA approach have a signiﬁcant increase
in the BNP after the procedure as compared to those who underwent TF. Addi-
tionally, the BNP levels at discharge was negatively correlated to residual aortic valve
gradient, left ventricular outﬂow tract diameter and left ventricular ejection fraction. L
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Background: Myocardial injury deﬁned occurs frequently following transcatheter
aortic valve implantation (TAVR). The aim of this study was to assess timing,predictors, and prognostic value of peri-procedural myocardial injury and chronic
troponin elevation after TAVR.
Methods: 276 patients (logistic EuroSCORE 26.617.1%) underwent transvascular
TAVR. In all patients, troponin I, CK-MB, and NT-proBNP levels were measured
before and after TAVR (1h, 4h, 24h, 48h, 72h, 7 days, 3, and 6 months).
Results: Myocardial injury (according to VARC-2 recommendation deﬁned as
DTrop 15x URL) occurred in 143/276 patients (51.8%) during the ﬁrst 72 hours
following TAVR. Use of a self-expanding prosthesis (p¼0.02), coronary artery disease
(p¼0.04), higher left-ventricular ejection fraction (LVEF) (p<0.001), and procedure
time (p<0.001) were independent predictors for the development of myocardial injury
after TAVR. 30-day (4.2% vs. 6.1%; p¼0.48) and 1-year mortality (19.4% vs. 26.5%;
p¼0.15) were not related to the incidence of peri-procedural myocardial injury.
However, patients with chronic troponin elevation after TAVR had an increased 1-
year mortality risk (HR 4.5, 95%-CI: 2.0-10.0; p<0.001).
Conclusion:Myocardial injury deﬁned as DTrop 15x URL after TAVR seems to be
a procedure-related issue but does not impact survival. However, a post-procedural
troponin increase might be useful for prognostication after TAVR.CRT-708
Initial US Experience with Commercial Transfemoral Edwards SAPIEN Transcatheter
Heart Valve Compared to Partner Cohort B for Inoperable Symptomatic Severe Aortic
Stenosis
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Background: TAVR using the Edwards SAPIEN valve is approved for commercial
use in the United States. This study aims to assess the clinical proﬁle, procedural
characteristics and in-hospital complications in patients treated with a commercial
SAPIEN valve outside the clinical trial context.
Methods: We retrospectively analyzed 69 consecutive inoperable patients who un-
derwent TAVR with a commercial SAPIEN valve compared to 55 PARTNER trial
patients from Cohort B enrolled in the same institution by the same Heart Team.
Results: Compared to the commercial group, patients in the PARTNER Cohort B
had higher mean STS score (105 vs. 94; p¼0.04) and a lower rate of peripheral
arterial disease (19% vs. 44%, p¼0.004). The majority of patients in the commercial
group had the procedure under conscious sedation (83% vs. 66%; p¼0.03). Planned
surgical cut-down for vascular access was rare in the commercial group (1.4% vs. 46%;
p <0.001). The overall rates of major vascular complications, life threatening or major
bleeding and blood transfusions were lower in commercial group (7.2% vs. 27%;
p¼0.003), (2.9% vs. 16%; p¼0.01), and (28% vs. 60%, p <0.001), respectively. In-
hospital all-cause mortality (5.8% vs. 9.1%; p¼0.51) and stroke rates (7.2% vs. 14.5%;
p¼0.19) were statistically not different between the groups. The median length of
hospitalization (p <0.001) and post-procedural length of stay (p¼0.01) was shorter in
the commercial group.
